Published in Diabetes Care on June 11, 2016
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
Diabetes Care: "Lagniappe" and "Seeing Is Believing"! Diabetes Care (2016) 0.77
ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia (2016) 0.76
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol (2017) 0.75
Diabetes Care: "Taking It to the Limit One More Time". Diabetes Care (2017) 0.75
The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. Diabetes Ther (2017) 0.75
Response: Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea (Diabetes Metab J 2016;40:482-93). Diabetes Metab J (2017) 0.75
Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR Res Protoc (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 7.27
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
How effective are treatments for diabetic retinopathy? JAMA (1993) 2.25
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology (2014) 1.89
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol (2007) 1.47
Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol (2012) 1.31
Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes (2014) 1.17
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care (2016) 0.95
Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med (2015) 0.94
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem (2013) 0.89
Systemic therapies for diabetic retinopathy: the accord eye study. Ophthalmology (2014) 0.80